Quintiles replaces CMO Cohen with Takeda's medical affairs director
This article was originally published in Scrip
Executive Summary
Quintiles has named the former medical affairs director of Takeda Pharmaceuticals, Dr Jeffrey A Spaeder, as its new chief medical and scientific officer. He succeeds Dr Oren Cohen who now leads Quintiles’s Phase I clinical research business. At Quintiles, Dr Spaeder will provide leadership in the ethical conduct of studies. He will chair Quintiles’s Drug Safety Committee and serve as vice-chair of Quintiles’ Council on Research Ethics. In addition to his work at Takeda, Dr Spaeder has also served as director of alliance management with Abbott Laboratories, where he managed clinical oncology research collaboration with a biotechnology partner.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"